|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| CRE loans | ||||||||||||||||||||
| Less: allowance for credit losses | ||||||||||||||||||||
| CRE loans, net | ||||||||||||||||||||
| Principal paydowns receivable | ||||||||||||||||||||
| Loan receivable - due from Manager | ||||||||||||||||||||
| Loan held for sale | ||||||||||||||||||||
| Investments in unconsolidated entities | ||||||||||||||||||||
| Properties held for sale | ||||||||||||||||||||
| Investments in real estate, net | ||||||||||||||||||||
| Right of use assets | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Accounts payable and other liabilities | ||||||||||||||||||||
| Management fee payable - related party | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Borrowings, net | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Distributions payable | ||||||||||||||||||||
| Accrued tax liability | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| EQUITY | ||||||||||||||||||||
| Preferred stock, value | ||||||||||||||||||||
| Common stock, par value $0.001: 41,666,666 shares authorized; 7,131,101 and 6,887,451 shares issued and outstanding (including 55,559 and 328,586 unvested restricted shares) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Distributions in excess of earnings | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Non-controlling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND EQUITY | ||||||||||||||||||||
Loading...
